tamoxifen + toremifene

Tamoxifen + toremifene is a combination of two selective estrogen receptor modulators (SERMs), both classified as nonsteroidal triphenylethylene derivatives. Each drug acts primarily as an estrogen receptor antagonist in breast tissue, inhibiting the proliferative action of estrogen on hormone receptor-positive breast cancer cells. Both agents also exhibit partial agonist effects in other tissues such as bone and endometrium, which can lead to distinct side effect profiles. Tamoxifen has been widely used since the 1970s for the treatment and prevention of estrogen receptor-positive breast cancer, while toremifene was developed later with a similar mechanism but some differences in metabolism and toxicity profile. The combination has been studied experimentally for potential additive or synergistic effects on tumor inhibition; however, available evidence suggests that simultaneous or sequential use does not provide significant additional benefit over monotherapy with either agent alone[1][2]. Both drugs are approved individually for hormone therapy in breast cancer.

Other names

tamoxifen citratetoremifene citrate